Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
June 2016, Vol 7, No 5
June 2016, Vol 7, No 5
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Tyrosine kinase inhibitors (TKIs) are the mainstay of therapy for patients with epidermal growth factor receptor (
EGFR
) mutation–positive non–small-cell lung cancer (NSCLC), according to the updated National Comprehensive Cancer Network (NCCN) NSCLC guideline. The NCCN guideline recommends
EGFR
testing as part of a broad molecular profiling in patients with NSCLC.
Read Article
ESR1 Mutations Predict Worse Survival in ER-Positive Advanced Breast Cancer
By
Phoebe Starr
Personalized Medicine
June 2016, Vol 7, No 5
A “liquid biopsy” was able to detect 2 mutations in the
ESR1
gene that predicted worse overall survival (OS) in women with estrogen receptor (ER)-positive metastatic breast cancer who were originally enrolled in the phase 3 BOLERO-2 clinical trial, according to results presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
In the Literature - June 2016
In the Literature
June 2016, Vol 7, No 5
Read Article
FDA News - June 2016
FDA Approvals, News & Updates
June 2016, Vol 7, No 5
Read Article
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Chemotherapy Use in Breast Cancer Declines with Gene-Based Assay
By
Charles Bankhead
Chemotherapy
,
Value in Oncology
,
Personalized Medicine
June 2016, Vol 7, No 5
Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene-based assay was used to guide treatment decision-making, according to new data presented at the 2016 American Association for Cancer Research meeting.
Read Article
Mutation Testing Encouraged for All Patients with Ovarian Cancer
By
Charles Bankhead
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma
By
Walter Alexander
Melanoma
June 2016, Vol 7, No 5
Read Article
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
The New World of Biosimilars
By
Meg Barbor, MPH
Value in Oncology
,
Biosimilars
June 2016, Vol 7, No 5
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma